Real-world data on the efficacy and safety of iruplinalkib (WX-0593) in ALK-positive advanced lung adenocarcinoma patients previously treated with lorlatinib.

Authors: Fen Wang, Zhu Li, Xiang Long, Qiushan He, Wanzhong Huang, Daying Wu, Lue Zhou

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.8638

Source: Full article

---

Abstract

8638